Evidence map›Paper›PMID 29872223›Full record

ArticleScientific reports2018

First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.

Itzhel García-Torres, Ignacio De la Mora-De la Mora, Gloria Hernández-Alcántara, Dora Molina-Ortiz, Silvia Caballero-Salazar, Alfonso Olivos-García, Gabriela Nava, Gabriel López-Velázquez, Sergio Enríquez-Flores

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Repurposing of rabeprazole as an anti-Journal of enzyme inhibition and medicinal chemistry · 2023
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Role of the Synthetic B1 Vitamin Sulbutiamine on Health.Journal of nutrition and metabolism · 2020
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Itzhel García-TorresGrupo de Investigación en Biomoléculas, Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Ciudad de México, 04530, Mexico.
Ignacio De la Mora-De la MoraGrupo de Investigación en Biomoléculas, Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Ciudad de México, 04530, Mexico.
Gloria Hernández-AlcántaraDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
Dora Molina-OrtizLaboratorio de Toxicología Genética, Instituto Nacional de Pediatría, Ciudad de México, 04530, Mexico.
Silvia Caballero-SalazarLaboratorio de Parasitología Experimental, Instituto Nacional de Pediatría, Ciudad de México, 04530, Mexico.
Alfonso Olivos-GarcíaUnidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México y Hospital General, Ciudad de México, 04510, Mexico.
Gabriela NavaDepartamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
Gabriel López-VelázquezGrupo de Investigación en Biomoléculas, Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Ciudad de México, 04530, Mexico. glv_1999@yahoo.com.
Sergio Enríquez-FloresGrupo de Investigación en Biomoléculas, Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Ciudad de México, 04530, Mexico. sergioenriquez@ciencias.unam.mx.
Instituto Nacional de Pediatria · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The microsporidia are a large group of intracellular parasites with a broad range of hosts, including humans. Encephalitozoon intestinalis is the second microsporidia species most frequently associated with gastrointestinal disease in humans, especially immunocompromised or immunosuppressed individuals, including children and the elderly. The prevalence reported worldwide in these groups ranges from 0 to 60%. Currently, albendazole is most commonly used to treat microsporidiosis caused by Encephalitozoon species. However, the results of treatment are variable, and relapse can occur. Consequently, efforts are being directed toward identifying more effective drugs for treating microsporidiosis, and the study of new molecular targets appears promising. These parasites lack mitochondria, and oxidative phosphorylation therefore does not occur, which suggests the enzymes involved in glycolysis as potential drug targets. Here, we have for the first time characterized the glycolytic enzyme triosephosphate isomerase of E. intestinalis at the functional and structural levels. Our results demonstrate the mechanisms of inactivation of this enzyme by thiol-reactive compounds. The most striking result of this study is the demonstration that established safe drugs such as omeprazole, rabeprazole and sulbutiamine can effectively inactivate this microsporidial enzyme and might be considered as potential drugs for treating this important disease.

Indexed as

AlbendazoleAmino Acid SequenceEncephalitozoonFungal ProteinsGastrointestinal DiseasesGene Expression Regulation, EnzymologicGene Expression Regulation, FungalHumansMicrosporidiaMicrosporidiosisOmeprazoleRabeprazoleSequence Homology, Amino AcidThiamineTriose-Phosphate IsomeraseAlbendazoleFungal ProteinsOmeprazoleRabeprazolesulbutiamineThiamineTriose-Phosphate Isomerase

Identifiers

PMID29872223
PMCPMC5988755
OpenAlexW2805211252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.